Compensating Participants in Clinical Research: Current Thinking

December 5, 2017

Sponsors, researchers and Institutional Review Boards (IRBs) are often wary about payments in research participation, citing concerns about coercion and undue influence, whether real or perceived, and have avoided payments that are “too high.” New research on how people make decisions about research participation, and new approaches to this question, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.Enter content here

Previous Flipbook
Balancing New with Common Recruitment Tactics
Balancing New with Common Recruitment Tactics

Next Flipbook
Removing Barriers: Reimbursement and Compensation for Participation in Oncology Clinical Trials
Removing Barriers: Reimbursement and Compensation for Participation in Oncology Clinical Trials

The impact of participant payments on clinical trial recruitment.